Abstract: An apparatus includes a remote optically pumped amplifier (ROPA). The ROPA includes a bypass filter configured to receive an optical signal and first pump power and to separate the optical signal and the first pump power. The ROPA also includes an amplifier configured to receive the optical signal from the bypass filter and to amplify the optical signal. The ROPA further includes an optical combiner/multiplexer configured to receive the first pump power from the bypass filter, receive at least second and third pump powers, combine at least two of the first, second and third pump powers, and provide different pump powers or combinations of pump powers to different locations within the ROPA to feed the amplifier.

Abstract: A pharmaceutical or cosmetic composition comprising an Indigo Naturalis or Indigo-producing plant extract for treating atopic dermatitis and any form of eczema, and a method of treating atopic dermatitis comprising administering a therapeutically effective amount of an Indigo Naturalis or Indigo-producing plant extract to a subject in need thereof are described.

Abstract: A pharmaceutical composition, as well as the use of composition in medical applications, are described.

Abstract: A pharmaceutical or cosmetic composition comprising an Indigo Naturalis or Indigo-producing plant extract for treating atopic dermatitis and any form of eczema, and a method of treating atopic dermatitis comprising administering a therapeutically effective amount of an Indigo Naturalis or Indigo-producing plant extract to a subject in need thereof are described.

Abstract: The present invention relates to a process for preparing an extract from one or more botanical raw materials, such as Indigo Naturalis and the extract itself. The present invention also relates to a composition comprising the extract, as well as the use of composition in medical or cosmetic applications.

Abstract: The present invention relates to a method of reducing cutaneous facial flushing caused by systemic use of phosphodiesterase type 5 (PDE5) inhibitors by topical facial dermatological application of an effective dose of a composition comprising at least one alpha adrenergic receptor agonist.

Abstract: Disclosed are ink compositions for printing patterns on substrates having non-stick fluororesin coatings. The ink compositions are particularly useful for printing decorative patterns or markings on cookware or bakeware to provide aesthetic and/or functional effects. Also disclosed are coated substrates which comprise non-stick coatings having patterns. Further disclosed are methods of manufacturing the coated substrates comprising non-stick coatings having patterns.

Abstract: A method of treating hand-foot syndrome (palmar-plantar erythrodysesthesia) and symptoms associated therewith in a patient undergoing or scheduled to undergo chemotherapy is claimed. The method involves topically administering a pharmaceutical composition comprising an effective amount of an alpha adrenergic receptor agonist, pharmaceutically acceptable salt thereof, or combinations thereof; and a pharmaceutically acceptable carrier to the affected areas of skin or to the hands and feet.

Abstract: A method of reducing hair loss (alopecia) in a patient undergoing or scheduled to undergo chemotherapy is claimed. The method involves administering brimonidine or a pharmaceutically acceptable salt thereof to the site of the hair follicles.

Abstract: A seat for a vehicle includes a seat pan, having a seat pan front edge and a seat pan rear edge, a backrest, having a backrest top edge and a backrest bottom edge, wherein the backrest bottom edge is articulately disposed adjacent to the seat pan rear edge, and a back support lattice disposed adjacent to the backrest. At least one of the seat pan and the backrest is configurable into a plurality of positions. The back support lattice is operatively connected to at least one of the seat pan and the backrest. The back support lattice provides adjustable back support depending upon one of the plurality of positions.

Abstract: An aircraft divan includes a lateral bracket connecting between front and rear legs with lateral bracket front and rear ends, a first track defined by the lateral bracket between the lateral bracket front and rear ends, an upright, having upright top and bottom ends, a second track defined by the upright between the upright top and bottom ends, a seat pan having seat pan front and rear ends, the seat pan being slidingly connected to the first track adjacent to the seat pan rear end, and a backrest having backrest top and bottom ends, the backrest being slidingly connected to the second track adjacent to the backrest top end. The seat pan rear end is pivotably connected to the backrest adjacent to the backrest bottom end such that movement of the seat pan is transmitted to the backrest so as to move together between upright and berth positions.

Abstract: An apparatus includes a remote optically pumped amplifier (ROPA). The ROPA includes a bypass filter configured to receive an optical signal and first pump power and to separate the optical signal and the first pump power. The ROPA also includes an amplifier configured to receive the optical signal from the bypass filter and to amplify the optical signal. The ROPA further includes an optical combiner/multiplexer configured to receive the first pump power from the bypass filter, receive at least second and third pump powers, combine at least two of the first, second and third pump powers, and provide different pump powers or combinations of pump powers to different locations within the ROPA to feed the amplifier.

Abstract: A combination of compounds is described for the treatment and/or prevention of skin conditions linked to hypopigmentation. Also described, is a combination product that includes at least one prostaglandin receptor agonist and at least one MC1R receptor agonist, as a medicament for use simultaneously, separately or spread out over time for the treatment and/or prevention of skin conditions linked to hypopigmentation, such as vitiligo.

Abstract: A rheology modifier copolymer of formula (I) wherein A is a polyacidic vinyl monomer selected from maleic, fumaric, itaconic, citraconic and acid combinations thereof and anhydrides and salts thereof, B is an acrylic or methacrylic acid or salt thereof; C is a C1-C8 ester of (meth)acrylic acid; D is an associative monomer; and optionally E is a crosslinking monomer.

Abstract: A rheology modifier copolymer of formula (I), wherein A is a macromonomer; B is an acrylic or methacrylic acid or salt thereof; C is a polyacidic vinyl monomer selected from maleic, fumaric, itaconic, citraconic and acids combinations thereof and anhydrides and salts thereof; and D optionally when present is a crosslinking monomer.

Abstract: A combination of compounds is described for the treatment and/or prevention of skin conditions linked to hypopigmentation. Also described, is a combination product that includes at least one prostaglandin receptor agonist and at least one MC1R receptor agonist, as a medicament for use simultaneously, separately or spread out over time for the treatment and/or prevention of skin conditions linked to hypopigmentation, such as vitiligo.

Abstract: The present invention relates to a method of reducing cutaneous facial flushing caused by systemic use of phosphodiesterase type 5 (PDE5) inhibitors by topical facial dermatological application of an effective dose of a composition comprising at least one alpha adrenergic receptor agonist.

Abstract: A rheology modifier copolymer of formula (I), wherein A is a macromonomer; B is an acrylic or methacrylic acid or salt thereof; C is a polyacidic vinyl monomer selected from maleic, fumaric, itaconic, citraconic and acids combinations thereof and anhydrides and salts thereof; and D optionally when present is a crosslinking monomer.